Presenting Author: Nicholas C Hazell
, Graduate Assistant at Univ. of Texas Med. Br., Galveston
Abstract:
The mRNA-lipid nanoparticle (mRNA-LNP) platform is versatile for development of vaccines and therapeutics, specifically for monoclonal antibody (mAb) treatment of viral disease. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected more than 760 million worldwide and contributes to nearly 7 million associated fatalities. As vaccines protect those immune-competent, the elderly and immune-compromised share increased risk for development of severe lung disease. In addition, virus evolution leads to novel variants that pose an enhanced threat to the aforementioned subpopulations, highlighting a need for therapeutics that can rapidly be developed to prevent severe disease in these high-risk populations. mAbs that neutralize are effective for treating SARS-CoV-2 infections with a number of mAbs targeting SARS-CoV-2 identified. We generated mRNAs expressing two different mAbs, LY-CoV1404 (mRNA-1404) and 76E1 (mRNA-76E1), that target different SARS-CoV-2 epitopes and formulated them in LNPs. In vitro analysis support both mRNAs can produce and secrete mAbs with epitope specificity in cells following transfection and in vivo studies exhibit durable antibody expression. Following single mRNA-LNP administration (5ug and 15ug dose via intramuscular or subcutaneous route), serum antibodies remained detectable 5 weeks out. Our data indicate that mRNA is a promising platform for the delivery of therapeutic mAbs to treat human disease such as viral infections.
mRNA delivery of epitope-specific monoclonal antibodies for treatment of viral infection
Category
Poster
Description
Custom CSS
double-click to edit, do not edit in source
Date: May 4 Presentation Time: 11:30 AM to 12:45 PM Room: Exhibit Hall F1